Search for content, post, videos

Small Cap Stocks News Recap: Lifelock Inc (NYSE:LOCK), Keryx Biopharmaceuticals (NASDAQ:KERX), MasTec, Inc. (NYSE:MTZ)

The $3.4 Trillion Market Regulators Still Can’t See Seven years ago this month, Wall Street titans like Lehman Brothers were brought to their knees in part because they lost access to a crucial type of short-term funding. Today, the market for repurchase agreements or “repos” is much smaller than it was in the lead-up to that panic. But it still represents $3.4 trillion in daily financial-system liabilities.

Skadden in Spotlight Over Yahoo’s Alibaba Spinoff Plan The IRS’s decision not to guarantee tax-free treatment to Yahoo Inc.’s spinoff of its Alibaba stake puts Yahoo’s lawyers at Skadden, Arps, Slate, Meagher & Flom LLP in the hot seat.

Lifelock Inc (NYSE:LOCK) finished last trade at $8.75, gaining 1.86%. Trading volume recorded for this company was about 1.40 million shares as compared to its average volume of 2.50 million shares. The share price rushed almost 14.98% in the last one month while its 52 week high is $19.15. The company has the total of 95.31 million outstanding shares while its market capitalization is now about $819.19 million. Lifelock Inc (NYSE:LOCK) Todd Davis, Chris Power, and Hilary Schneider, President, will present at the Deutsche Bank Technology, Media, and Telecom Conference in Las Vegas, NV. This presentation is planned for Thursday, September 17, 2015 at 6:20 p.m. Eastern Time, or 3:20 p.m. Pacific Time.

Can LOCK Extend this Gain Stream? Find Out in This Trend Analysis Report

Keryx Biopharmaceuticals (NASDAQ:KERX) closed at $ 4.61, down -2.95%, on volume of over 1.40 million shares.  The share price fell -28.19% in the last 5 days. The company has an average trading volume of 1.82 million shares. In the time frame of the last one month, shares dropped almost -27.29%. Its market capitalization was $500.65 million. Keryx Biopharmaceuticals (NASDAQ:KERX) declared its financial results for the second quarter ended June 30, 2015.

BUSINESS HIGHLIGHTS

Auryxia U.S. Commercialization

  • Net U.S. Auryxia product sales for the second quarter were approximately $1.8 million, based on approximately 3,700 Auryxia prescriptions, as reported to the company by IMS Health and specialty pharmacies that do not report data to IMS, including DaVita Rx and Fresenius Rx.
  • Unrestricted access for Auryxia increased to 65 percent across Medicare Part D and commercial insurance providers, with the addition of Auryxia on the formularies of two national Part D insurance providers that began processing claims in the third quarter of 2015.
  • Keryx’s sales representatives have reached more than 75 percent of the 5,000 prescriber targets; approximately 1,000 target prescribers have written a prescription for Auryxia.
  • Keryx successfully introduced samples into the market in the second quarter, with approximately 6,000 starter kits shipped to approximately 1,300 target prescribers — the majority of whom had not previously prescribed Auryxia.

How Should Investors React to KERX Now? Find Out in this Trend Analysis Report

MasTec, Inc. (NYSE:MTZ) traded with -0.91% lost momentum to $17.47 in the latest trading session It captured $1.40 billion in market value. The total number of shares traded on the latest trading day was about 79.84 million shares. The day started out with an opening price of $17.75 and changed hands at price range of $17.43 to $32.10 apiece. MasTec, Inc. (NYSE:MTZ) second quarter financial results and updated its guidance for the balance of the year.

Second quarter 2015 revenue reduced 3.7% to $1.07 billion from $1.1 billion in the preceding year quarter.  The quarterly revenue change was primarily composed of revenue declines in the Electrical Transmission and Communications segments, partially offset by revenue enhances in the Oil & Gas and Power Generation & Industrial segments. Second quarter 2015 net loss from ongoing operations was $3.8 million, or $0.05 per diluted share, contrast to net income from ongoing operations of $33.7 million, or $0.39 per diluted share, for the second quarter of 2014. Second quarter 2015 results comprise about $0.14 per diluted share for non-operating and non-core charges not comprised of in preceding year results, composed primarily of WesTower acquisition integration costs, Audit Committee investigation related costs and the nonrecurring impact of an income tax law change in Alberta, Canada.

Get a Free Report and Detailed Analysis on MTZ Click Here to Read